Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ARIAD Pharmaceuticals, Inc.

http://www.ariad.com

Latest From ARIAD Pharmaceuticals, Inc.

Coronavirus Update: EU Demands AstraZeneca Meets Its Vaccines Commitments After Supply Warning

Plus Takeda starts vaccine trial in Japan and South Korea clears Celltrion's antibody therapeutic. 

Commercial Companies

Merck & Co. Pivots To COVID-19 Treatments After Vaccines Disappoint

The company cited lackluster efficacy in its decision to discontinue development of V590 and V591. It will instead develop two drugs to treat COVID-19.

Research & Development BioPharmaceutical

Scrip Asks…What Does 2021 Hold For Biopharma? Part 2: COVID-19 Shock Waves And Silver Linings

Executives expect the changes wrought by necessity in the face of a global pandemic to have lasting effects, both positive and negative, on the biopharma sector. Here they share their predictions for the coming year.

Coronavirus COVID-19 Research and Development Strategies

Lessons Learned And What's Ahead: I-Mab, JW, RemeGen CEOs On Biotech Financing

Top executives from three high-flying Chinese biotechs, all of which have gone public on Nasdaq and in Hong Kong, offered lessons learned and looked forward to what’s ahead in a panel session at the recent JPM conference.

China Financing
See All

Company Information

UsernamePublicRestriction

Register